NCE-1 Intelligence & Market Opportunity

Amondys 45

Casimersen

Neuromuscular agents

Intravenous Solution

Approval Date

25-Feb-21

NCE-1 Date

25-Feb-25

NCE Date

25-Feb-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

280

2027

267

2028

221

2029

190

2030

170

2031

139

2032

118

Molecule profile

Details & specifications

Molecule

Casimersen

Innovator

SAREPTA THERAPEUTICS, INC.

Dosage Form

Intravenous Solution

Strength

100 mg/2 mL (50 mg/mL)

Therapeutic Category

Neuromuscular agents

Usage

To treat Duchenne muscular dystrophy

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.